CD55-deficient Protein-losing Enteropathy
0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
3100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
RegeneronTARRYTOWN, NY
3 programsPozelimabN/AMonoclonal Antibody1 trial
PozelimabN/AMonoclonal Antibody1 trial
PozelimabPHASE_2_3Monoclonal Antibody1 trial
Active Trials
NCT05232110Approved For Marketing
NCT06003881Approved For Marketing
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
RegeneronPozelimab
Clinical Trials (3)
Total enrollment: 10 patients across 3 trials
Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
Start: Jan 2020Est. completion: May 202410 patients
Phase 2/3Completed
Compassionate Use of Pozelimab
N/AApproved For Marketing
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
N/AApproved For Marketing
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.